6 results about "Pharmasolve" patented technology

A bremelanotide pharmaceutical composition, a formulation thereof, a preparation method therefor, and use thereof. The bremelanotide pharmaceutical composition comprises bremelanotide as a pharmaceutically active ingredient, a solvent, and a polymer. The solvent includes one or more of N-methylpyrrolidone, polyethylene glycol, dimethyl sulfoxide, and benzyl benzoate and enables the plasma concentration of bremelanotide to be stably greater than 0.1 ng / mL at 120-168 h, thereby achieving the target sustained release. The bremelanotide pharmaceutical composition can be directly injected and does not require the addition of a thickener, a gel-forming agent, or other excipients.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.

The invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, an oily phase and at least a) a phenyl silicone oil of formula (I) [Chem 1] (I) wherein—Me is methyl and Ph is phenyl, OR′ represents an —OSiMe3 group, —y ranges from 1 to 1000, and—z ranges from 1 to 1000, b) a C8-C30 fatty alcohol, c) a branched dextrin ester, and d) advantageously a liposoluble polymer selected from among the group consisting of: (i) acrylate polymers selected from among the group consisting of silicone acrylate polymers, acrylate polymers comprising an alkyl chain of at least 10 carbon atoms, and copolymers of acrylates and acrylamide, (ii) copolymers of vinylpyrrolidone (VP) and alkene comprising at least 18 carbon atoms, and (iii) mixtures thereof, and its use in particular on the lips for a make-up result with improved gloss and longer-lasting gloss and color. Preferably, the composition is in a semi-solid or solid form.

The present invention belongs to the field of biopharmaceuticals and provides a κ-opioid receptor agonist having the following formula, its stereoisomers, and pharmaceutically acceptable salts thereof. The κ-opioid receptor agonist has high selectivity for the κ-opioid receptor, its activity is 3 to 15 times that of diferikephalin, and has high pharmacological activity, and can be used for the treatment, prevention and / or remission of pruritus, and / or analgesia. D-Phe-AA1-AA2-D-Lys-4-aminopiperidine-4-carboxamide-AA3-AA4-AA5 [Formula I].

The invention relates to the technical field of pharmaceutical preparations, and particularly provides a brexpiprazole sustained-release injection based on in-situ phase change gel as well as a preparation method and application of the brexpiprazole sustained-release injection. The brexpiprazole sustained-release injection is prepared from brexpiprazole, N-methyl pyrrolidone and a polylactic acid-glycolic acid copolymer according to the weight ratio of (0.1 to 0.2): (3 to 3.8): 1, wherein the intrinsic viscosity of the polylactic acid-glycolic acid copolymer is (0.1 to 0.3) dL / g. The preparation process of the brexpiprazole sustained-release injection is relatively simple and convenient, and the brexpiprazole sustained-release injection is a homogeneous solution before injection, so that the injection tolerance of a patient is effectively improved; the inherent problems that brexpiprazole is extremely high in hydrophobicity, rapid in-vivo elimination and free of remarkable central activity of metabolites are solved, stable slow release of blood concentration for several weeks is achieved, the drug release kinetics is highly predictable and good in reproducibility, and the purposes of reducing the drug administration frequency and improving the patient compliance are achieved.

The present invention aims to provide an injectable pharmaceutical composition containing diferikephalin that can reduce human error and labor associated with dosage preparation in medical settings. [Solution] The present invention relates to an injectable pharmaceutical composition containing diferikephalin or a pharmacoagulably acceptable salt thereof for the treatment of pruritus in dialysis patients, wherein the injectable pharmaceutical composition is designed to reduce human error and labor associated with dosage preparation in medical settings, and the injectable pharmaceutical composition contains diferikephalin or a pharmacoagulably acceptable salt thereof in amounts of 17.5 μg, 25.0 μg, 35.0 μg, or 42.5 μg in free form equivalent, and relates to an injectable pharmaceutical composition for administration to dialysis patients with a dry weight of less than 45 kg, 45 kg or more but less than 65 kg, 65 kg or more but less than 85 kg, or 85 kg or more, respectively.